NASDAQ:AKAO - Achaogen Stock Price, Price Target & More

$13.04 +0.36 (+2.84 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$13.04
Today's Range$12.42 - $13.20
52-Week Range$9.83 - $27.49
Volume1.47 million shs
Average Volume1.22 million shs
Market Capitalization$551.91 million
P/E Ratio-4.11
Dividend YieldN/A
Beta1.04

About Achaogen (NASDAQ:AKAO)

Achaogen logoAchaogen, Inc., a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.

Receive AKAO News and Ratings via Email

Sign-up to receive the latest news and ratings for AKAO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKAO
CUSIPN/A
Phone650-800-3636

Debt

Debt-to-Equity Ratio0.08%
Current Ratio4.83%
Quick Ratio4.83%

Price-To-Earnings

Trailing P/E Ratio-4.11
Forward P/E Ratio-3.75
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.18 million
Price / Sales52.16
Cash FlowN/A
Price / CashN/A
Book Value$2.88 per share
Price / Book4.53

Profitability

EPS (Most Recent Fiscal Year)($3.17)
Net Income$-125,610,000.00
Net Margins-1,124.10%
Return on Equity-83.14%
Return on Assets-52.31%

Miscellaneous

Employees230
Outstanding Shares44,720,000

How to Become a New Pot Stock Millionaire

Achaogen (NASDAQ:AKAO) Frequently Asked Questions

What is Achaogen's stock symbol?

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

How were Achaogen's earnings last quarter?

Achaogen (NASDAQ:AKAO) posted its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing the Zacks' consensus estimate of ($0.77) by $0.21. The biopharmaceutical company had revenue of $1.87 million for the quarter, compared to analyst estimates of $1.18 million. Achaogen had a negative return on equity of 83.14% and a negative net margin of 1,124.10%. View Achaogen's Earnings History.

What price target have analysts set for AKAO?

10 brokers have issued 12 month target prices for Achaogen's stock. Their predictions range from $14.00 to $29.00. On average, they expect Achaogen's stock price to reach $23.1250 in the next twelve months. View Analyst Ratings for Achaogen.

What are Wall Street analysts saying about Achaogen stock?

Here are some recent quotes from research analysts about Achaogen stock:
  • 1. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (2/14/2018)
  • 2. Mizuho analysts commented, "We believe the recent price pullback from 52-week highs presents a buying opportunity especially considering Plazomicin represents meaningful advances in the aminoglycoside class with survival benefits ." (11/9/2017)

Who are some of Achaogen's key competitors?

Who are Achaogen's key executives?

Achaogen's management team includes the folowing people:
  • Mr. Blake Wise, CEO & Director (Age 47)
  • Dr. Kenneth J. Hillan, Pres of R&D, Pres of Achaogen and Director (Age 57)
  • Dr. Floyd E. Romesberg Ph.D., Principal Scientific Founder and Advisor
  • Dr. Nathaniel E. David A.B., Ph.D., Principal Entrepreneurial Founder (Age 50)
  • Mr. Tobin C. Schilke, Chief Financial Officer & Principal Accounting Officer (Age 43)

Has Achaogen been receiving favorable news coverage?

News articles about AKAO stock have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Achaogen earned a news impact score of 0.03 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 45.42 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Achaogen?

Shares of AKAO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achaogen's stock price today?

One share of AKAO stock can currently be purchased for approximately $13.04.

How big of a company is Achaogen?

Achaogen has a market capitalization of $551.91 million and generates $11.18 million in revenue each year. The biopharmaceutical company earns $-125,610,000.00 in net income (profit) each year or ($3.17) on an earnings per share basis. Achaogen employs 230 workers across the globe.

How can I contact Achaogen?

Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-800-3636 or via email at [email protected]


MarketBeat Community Rating for Achaogen (AKAO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  262 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  425
MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe AKAO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKAO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Achaogen (NASDAQ:AKAO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for Achaogen in the last 12 months. Their average twelve-month price target is $23.1250, suggesting that the stock has a possible upside of 77.34%. The high price target for AKAO is $29.00 and the low price target for AKAO is $14.00. There are currently 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.912.902.89
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.1250$23.7778$25.4444$28.1250
Price Target Upside: 77.34% upside116.16% upside128.20% upside84.31% upside

Achaogen (NASDAQ:AKAO) Consensus Price Target History

Price Target History for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ:AKAO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/4/2018Leerink SwannReiterated RatingOutperformLowView Rating Details
3/1/2018HC WainwrightLower Price TargetBuy -> Buy$31.00 -> $29.00HighView Rating Details
2/28/2018William BlairReiterated RatingOutperformHighView Rating Details
2/28/2018Stifel NicolausLower Price TargetBuy -> Buy$27.00 -> $23.00MediumView Rating Details
2/28/2018Needham & Company LLCReiterated RatingBuy -> Buy$29.00 -> $20.00MediumView Rating Details
2/14/2018WedbushReiterated RatingPositive -> Outperform$28.00 -> $22.00HighView Rating Details
1/10/2018GuggenheimReiterated RatingBuy$14.00HighView Rating Details
1/3/2018MizuhoReiterated RatingBuy$28.00HighView Rating Details
1/3/2018SunTrust BanksLower Price TargetBuy$27.00HighView Rating Details
5/15/2017CowenReiterated RatingOutperformN/AView Rating Details
3/30/2017AegisDowngradeBuy -> Hold$29.00LowView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Achaogen (NASDAQ:AKAO) Earnings History and Estimates Chart

Earnings by Quarter for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ:AKAO) Earnings Estimates

2018 EPS Consensus Estimate: ($3.65)
2019 EPS Consensus Estimate: ($3.18)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($1.00)($0.85)($0.93)
Q2 20183($1.02)($0.96)($0.99)
Q3 20184($1.01)($0.77)($0.89)
Q4 20184($0.91)($0.81)($0.85)
Q1 20191($0.85)($0.85)($0.85)
Q2 20191($0.81)($0.81)($0.81)
Q3 20191($0.78)($0.78)($0.78)
Q4 20191($0.74)($0.74)($0.74)

Achaogen (NASDAQ AKAO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018Q4 2017($0.77)($0.98)$1.18 million$1.87 millionViewListenView Earnings Details
11/8/2017Q3($0.72)($0.85)$2.09 million$0.58 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.60)($0.78)$2.69 million$1.30 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.54)($0.93)$3.81 million$7.46 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.49)($1.04)$13.33 million$10.73 millionViewN/AView Earnings Details
11/7/2016Q3($0.61)($0.41)$8.72 million$16.05 millionViewListenView Earnings Details
8/8/2016Q2($0.67)($0.87)$5.58 million$9.14 millionViewN/AView Earnings Details
5/5/2016Q1 2016($0.60)($0.66)$5.21 million$5.85 millionViewN/AView Earnings Details
3/15/2016Q414($0.58)($0.61)$5.33 million$4.70 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.46)($0.48)$5.10 million$4.48 millionViewN/AView Earnings Details
8/10/2015Q2 2015($0.20)($0.05)$8.65 million$12.04 millionViewN/AView Earnings Details
5/11/2015Q1 2015($0.25)($0.34)$5.00 million$4.88 millionViewN/AView Earnings Details
3/16/2015Q4 2014($0.33)($0.27)$4.96 million$4.26 millionViewN/AView Earnings Details
11/10/2014Q314($0.18)($0.47)$6.00 million$4.52 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.19)($0.20)$5.99 million$5.20 millionViewN/AView Earnings Details
5/12/2014Q114($0.21)($1.00)$5.39 million$6.00 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Achaogen (NASDAQ:AKAO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Achaogen (NASDAQ AKAO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.36%
Institutional Ownership Percentage: 77.37%
Insider Trading History for Achaogen (NASDAQ:AKAO)
Institutional Ownership by Quarter for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ AKAO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/4/2018Robert W DugganMajor ShareholderBuy47,361$12.44$589,170.846,411,108View SEC Filing  
4/2/2018Robert W DugganMajor ShareholderBuy20,000$12.51$250,200.006,411,108View SEC Filing  
3/28/2018Robert W DugganMajor ShareholderBuy30,000$12.44$373,200.006,391,108View SEC Filing  
3/20/2018Robert W DugganMajor ShareholderBuy36,300$11.12$403,656.006,336,108View SEC Filing  
3/15/2018Robert W DugganMajor ShareholderBuy49,660$11.36$564,137.606,294,808View SEC Filing  
3/13/2018Kenneth J. HillanInsiderSell2,735$11.74$32,108.90View SEC Filing  
3/12/2018Robert W DugganMajor ShareholderBuy20,000$11.39$227,800.006,255,148View SEC Filing  
3/9/2018Robert W DugganMajor ShareholderBuy50,000$11.41$570,500.006,255,148View SEC Filing  
3/2/2018Robert W DugganMajor ShareholderBuy527,396$10.31$5,437,452.765,697,752View SEC Filing  
2/28/2018Robert W DugganMajor ShareholderBuy20,000$10.70$214,000.005,697,752View SEC Filing  
2/21/2018Blake WiseCEOSell1,640$10.67$17,498.80View SEC Filing  
2/21/2018Kenneth J. HillanInsiderSell4,606$10.67$49,146.02View SEC Filing  
2/21/2018Tobin SchilkeCFOSell1,108$10.67$11,822.36View SEC Filing  
2/14/2018Robert W DugganMajor ShareholderBuy10,000$10.96$109,600.005,668,310View SEC Filing  
1/5/2018Robert W DugganMajor ShareholderBuy50,000$11.51$575,500.005,617,752View SEC Filing  
1/3/2018Robert W DugganMajor ShareholderBuy15,000$10.89$163,350.005,617,752View SEC Filing  
12/18/2017Robert W DugganMajor ShareholderBuy95,012$11.13$1,057,483.565,602,752View SEC Filing  
9/26/2017Blake WiseCOOSell3,576$15.99$57,180.24View SEC Filing  
9/26/2017Gary LoebGeneral CounselSell1,146$15.99$18,324.54View SEC Filing  
6/12/2017Tobin SchilkeCFOSell2,066$21.53$44,480.98View SEC Filing  
1/26/2017Gary LoebGeneral CounselSell521$16.78$8,742.38View SEC Filing  
1/26/2017Ian FriedlandInsiderSell695$16.78$11,662.10View SEC Filing  
1/26/2017Kenneth J. HillanCEOSell1,431$16.78$24,012.18View SEC Filing  
1/26/2017Tobin SchilkeCFOSell955$16.78$16,024.90View SEC Filing  
1/26/2017Zeryn SarpangalVPSell781$16.78$13,105.18View SEC Filing  
12/19/2016Equity Opportunities Iv GrowthMajor ShareholderBuy500,000$13.50$6,750,000.00View SEC Filing  
9/27/2016Blake WiseCOOSell3,632$4.30$15,617.60View SEC Filing  
9/27/2016Zeryn SarpangalVPSell1,069$4.30$4,596.70View SEC Filing  
3/17/2016Ian FriedlandInsiderSell1,772$3.22$5,705.8432,728View SEC Filing  
3/17/2016Kenneth J HillanCEOSell3,572$3.22$11,501.8461,628View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Achaogen (NASDAQ AKAO) News Headlines

Source:
DateHeadline
An In-Depth Look at Achaogen’s Cash FlowAn In-Depth Look at Achaogen’s Cash Flow
finance.yahoo.com - April 19 at 8:06 AM
Achaogen’s Financial PerformanceAchaogen’s Financial Performance
finance.yahoo.com - April 18 at 5:54 PM
A Look at Achaogen’s Research PipelineA Look at Achaogen’s Research Pipeline
finance.yahoo.com - April 18 at 5:54 PM
Q1 2018 EPS Estimates for Achaogen (AKAO) Raised by AnalystQ1 2018 EPS Estimates for Achaogen (AKAO) Raised by Analyst
www.americanbankingnews.com - April 18 at 7:58 AM
 Analysts Expect Achaogen (AKAO) Will Post Quarterly Sales of $1.25 Million Analysts Expect Achaogen (AKAO) Will Post Quarterly Sales of $1.25 Million
www.americanbankingnews.com - April 18 at 4:32 AM
Achaogen (AKAO) Forecasted to Post FY2021 Earnings of $1.31 Per ShareAchaogen (AKAO) Forecasted to Post FY2021 Earnings of $1.31 Per Share
www.americanbankingnews.com - April 17 at 7:07 AM
BidaskClub Downgrades Achaogen (AKAO) to HoldBidaskClub Downgrades Achaogen (AKAO) to Hold
www.americanbankingnews.com - April 16 at 9:16 PM
Specialty Report On Infectious Disease: Unlocking The Upcoming Binary Event Of Achaogen And Value Of MelintaSpecialty Report On Infectious Disease: Unlocking The Upcoming Binary Event Of Achaogen And Value Of Melinta
seekingalpha.com - April 16 at 8:06 AM
Achaogen (AKAO) Expected to Post Earnings of -$0.92 Per ShareAchaogen (AKAO) Expected to Post Earnings of -$0.92 Per Share
www.americanbankingnews.com - April 16 at 5:19 AM
Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious ...Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious ...
globenewswire.com - April 10 at 5:38 PM
Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
finance.yahoo.com - April 10 at 8:13 AM
Achaogen (AKAO) Now Covered by GuggenheimAchaogen (AKAO) Now Covered by Guggenheim
www.americanbankingnews.com - April 5 at 9:00 PM
Insider Buying: Achaogen (AKAO) Major Shareholder Acquires 20,000 Shares of StockInsider Buying: Achaogen (AKAO) Major Shareholder Acquires 20,000 Shares of Stock
www.americanbankingnews.com - April 4 at 10:57 PM
Robert W. Duggan Buys 47,361 Shares of Achaogen (AKAO) StockRobert W. Duggan Buys 47,361 Shares of Achaogen (AKAO) Stock
www.americanbankingnews.com - April 4 at 10:38 PM
A Billionaires Latest Biotech BetA Billionaire's Latest Biotech Bet
www.barrons.com - April 4 at 4:24 PM
[$$] A Billionaires Latest Biotech Bet[$$] A Billionaire's Latest Biotech Bet
finance.yahoo.com - April 4 at 4:24 PM
Achaogen (AKAO) Stock Rating Upgraded by ValuEngineAchaogen (AKAO) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 3 at 8:10 PM
$1.25 Million in Sales Expected for Achaogen (AKAO) This Quarter$1.25 Million in Sales Expected for Achaogen (AKAO) This Quarter
www.americanbankingnews.com - April 1 at 4:38 AM
Mizuho Reaffirms "Buy" Rating for Achaogen (AKAO)Mizuho Reaffirms "Buy" Rating for Achaogen (AKAO)
www.americanbankingnews.com - March 31 at 8:16 PM
Stifel Nicolaus Cuts Achaogen (AKAO) Price Target to $27.00Stifel Nicolaus Cuts Achaogen (AKAO) Price Target to $27.00
www.americanbankingnews.com - March 31 at 7:42 PM
Form 4 Achaogen Inc For: Mar 28 Filed by: DUGGAN ROBERT WForm 4 Achaogen Inc For: Mar 28 Filed by: DUGGAN ROBERT W
www.streetinsider.com - March 31 at 8:09 AM
SunTrust Banks Trims Achaogen (AKAO) Target Price to $27.00SunTrust Banks Trims Achaogen (AKAO) Target Price to $27.00
www.americanbankingnews.com - March 30 at 11:42 PM
Insider Buying: Achaogen (AKAO) Major Shareholder Buys 30,000 Shares of StockInsider Buying: Achaogen (AKAO) Major Shareholder Buys 30,000 Shares of Stock
www.americanbankingnews.com - March 30 at 10:14 PM
Achaogens (AKAO) Buy Rating Reaffirmed at MizuhoAchaogen's (AKAO) Buy Rating Reaffirmed at Mizuho
www.americanbankingnews.com - March 30 at 10:02 PM
Edited Transcript of AKAO earnings conference call or presentation 27-Feb-18 9:30pm GMTEdited Transcript of AKAO earnings conference call or presentation 27-Feb-18 9:30pm GMT
finance.yahoo.com - March 30 at 5:41 PM
 Brokerages Anticipate Achaogen Inc (AKAO) Will Post Earnings of -$0.92 Per Share Brokerages Anticipate Achaogen Inc (AKAO) Will Post Earnings of -$0.92 Per Share
www.americanbankingnews.com - March 30 at 8:06 AM
Research Analysts Set Expectations for Achaogen Incs FY2022 Earnings (AKAO)Research Analysts Set Expectations for Achaogen Inc's FY2022 Earnings (AKAO)
www.americanbankingnews.com - March 30 at 7:40 AM
Zacks Investment Research Lowers Achaogen (AKAO) to SellZacks Investment Research Lowers Achaogen (AKAO) to Sell
www.americanbankingnews.com - March 29 at 9:04 PM
Guggenheim Reiterates Buy Rating for Achaogen (AKAO)Guggenheim Reiterates Buy Rating for Achaogen (AKAO)
www.americanbankingnews.com - March 29 at 3:00 PM
Achaogen Inc (AKAO) Given Consensus Rating of "Buy" by BrokeragesAchaogen Inc (AKAO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 28 at 8:08 AM
2 Small Biotechs That Continue to Look Good2 Small Biotechs That Continue to Look Good
finance.yahoo.com - March 25 at 6:32 PM
Achaogen (AKAO) Price Target Increased to $31.00 by Analysts at HC WainwrightAchaogen (AKAO) Price Target Increased to $31.00 by Analysts at HC Wainwright
www.americanbankingnews.com - March 25 at 8:16 AM
Achaogen (AKAO) Given New $29.00 Price Target at HC WainwrightAchaogen (AKAO) Given New $29.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 24 at 2:12 PM
Achaogen: Not Too Late To Catch The RallyAchaogen: Not Too Late To Catch The Rally
seekingalpha.com - March 23 at 5:54 PM
Achaogen: Contrarian Play At An Inflection Point - Seeking Alpha - Seeking AlphaAchaogen: Contrarian Play At An Inflection Point - Seeking Alpha - Seeking Alpha
seekingalpha.com - March 23 at 8:08 AM
Financial Contrast: Achaogen (AKAO) and XBiotech (XBIT)Financial Contrast: Achaogen (AKAO) and XBiotech (XBIT)
www.americanbankingnews.com - March 23 at 5:32 AM
Achaogen (AKAO) Says FDA Advisory Committee Meeting for Plazomicin Set for May 2Achaogen (AKAO) Says FDA Advisory Committee Meeting for Plazomicin Set for May 2
www.streetinsider.com - March 22 at 5:46 PM
Achaogen Announces Date of FDA Advisory Committee Meeting for Plazomicin - GlobeNewswire (press release)Achaogen Announces Date of FDA Advisory Committee Meeting for Plazomicin - GlobeNewswire (press release)
globenewswire.com - March 22 at 8:13 AM
Achaogen Inc (AKAO) Major Shareholder Robert W. Duggan Acquires 36,300 SharesAchaogen Inc (AKAO) Major Shareholder Robert W. Duggan Acquires 36,300 Shares
www.americanbankingnews.com - March 21 at 7:32 PM
Achaogen Announces Date of FDA Advisory Committee Meeting for PlazomicinAchaogen Announces Date of FDA Advisory Committee Meeting for Plazomicin
finance.yahoo.com - March 21 at 8:26 AM
Robert W. Duggan Acquires 49,660 Shares of Achaogen Inc (AKAO) StockRobert W. Duggan Acquires 49,660 Shares of Achaogen Inc (AKAO) Stock
www.americanbankingnews.com - March 16 at 7:52 PM
Insider Selling: Achaogen Inc (AKAO) Insider Sells 2,735 Shares of StockInsider Selling: Achaogen Inc (AKAO) Insider Sells 2,735 Shares of Stock
www.americanbankingnews.com - March 15 at 10:26 PM
Achaogen Inc (AKAO) Expected to Announce Quarterly Sales of $1.25 MillionAchaogen Inc (AKAO) Expected to Announce Quarterly Sales of $1.25 Million
www.americanbankingnews.com - March 15 at 2:58 PM
Achaogen to Present at Needham & Companys 17th Annual Healthcare Conference - GlobeNewswire (press release)Achaogen to Present at Needham & Company's 17th Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 15 at 8:06 AM
Achaogen to Present at Needham & Company’s 17th Annual Healthcare ConferenceAchaogen to Present at Needham & Company’s 17th Annual Healthcare Conference
finance.yahoo.com - March 14 at 8:14 AM
Insider Buying: Achaogen Inc (AKAO) Major Shareholder Purchases 20,000 Shares of StockInsider Buying: Achaogen Inc (AKAO) Major Shareholder Purchases 20,000 Shares of Stock
www.americanbankingnews.com - March 13 at 8:17 PM
Robert W. Duggan Buys 50,000 Shares of Achaogen Inc (AKAO) StockRobert W. Duggan Buys 50,000 Shares of Achaogen Inc (AKAO) Stock
www.americanbankingnews.com - March 13 at 7:34 PM
Wired News – Cellectar Biosciences to Present Results from Phase-1 Study of CLR 124 Uptake in Brain Tumors at the World Congress of the World Federation of Nuclear Medicine and BiologyWired News – Cellectar Biosciences to Present Results from Phase-1 Study of CLR 124 Uptake in Brain Tumors at the World Congress of the World Federation of Nuclear Medicine and Biology
finance.yahoo.com - March 8 at 8:09 AM
Achaogen (AKAO) Rating Reiterated by Leerink SwannAchaogen (AKAO) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - March 7 at 10:59 AM
Leerink Swann Weighs in on Achaogen Incs Q1 2018 Earnings (AKAO)Leerink Swann Weighs in on Achaogen Inc's Q1 2018 Earnings (AKAO)
www.americanbankingnews.com - March 7 at 8:16 AM

SEC Filings

Achaogen (NASDAQ:AKAO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Achaogen (NASDAQ:AKAO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Achaogen (NASDAQ AKAO) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.